ANTICOV: Largest Clinical Trial in Africa to Test New Drug Combination (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/anticov-largest-clinical-trial-in-africa-to-test-new-drug-combination
trial started in September 2020 with the HIV antiretroviral combination lopinavir/ritonavir and the malaria drug hydroxychloroquine. These two initial arms were suspended in December 2020 after WHO updated
Combating Over-Prescription of Antibiotics in Children: A Swiss-Tanzanian Digital Health Innovation with Promising Results (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/lutte-contre-la-surprescription-dantibiotiques-chez-les-enfants-une-innovation-helvetico-tanzanienne-aux-resultats-prometteurs
action Bacterial antimicrobial resistance was responsible for 1.27 million deaths in 2019, as much as malaria and HIV combined. Inappropriate use of antibiotics is a major factor in this problem. In Tanzania
Winter Symposium 2020 (Page)
https://www.swisstph.ch/fr/about/events/winter-symposium-2020
a Public Private Partnership from Manufacturer to Health Facility, Hans Rietveld, Medicines for Malaria Venture 09:40 Stock-Outs in Switzerland, Enea Martinelli, pharmaSuisse Session 2 | Supply Chains
A Warm Welcome to Our New Students (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/a-warm-welcome-to-our-new-students
start of a semester is a moment of renewed excitement and opportunity,” said Till Voss , Head of the Malaria Gene Regulation unit. “We are delighted to welcome new students to the MSc Infection Biology programme
2.5 Million Euro Grant Awarded to Swiss TPH for Tuberculosis Research (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/25-million-euro-grant-awarded-to-swiss-tph-for-tuberculosis-research
disease, claiming over 4,000 lives each day. This equates to more daily casualties than HIV/AIDS and malaria combined. It is also the biggest killer of all antimicrobial resistant (AMR) related deaths. Gagneux's
New Compounds Show Promise in Transforming Treatment of Parasitic Diseases (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/new-compounds-show-promise-in-transforming-treatment-of-parasitic-diseases
expertise and drug discovery For 30 years, Swiss TPH has been one of the leaders in drug discovery for malaria and neglected tropical diseases, such as infections by helminths or trypanosomatids and Buruli Ulcer
Swiss TPH Symposium: Global Health in the 21st Century (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/swiss-tph-symposium-global-health-in-the-21st-century
a round of speed talks on topics such as infectious and chronic diseases, antibiotic resistance, malaria control, tuberculosis, HIV and the role of migration in disease transmission. Julia Bielicki from
“Climate Change is Becoming One of the Biggest Global Health Threats” (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/climate-change-is-becoming-one-of-the-biggest-global-health-threats
on and ecology - we see increasing temperatures creating a breeding ground for diseases such as malaria and dengue, which are transmitted through mosquitos. Do you think enough is being done to combat
«Die Entwicklung neuer Medikamente ist Teamwork» (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/die-entwicklung-neuer-medikamente-ist-teamwork
für den Erfolg des Swiss TPH bei der Entwicklung neuer Medikamente gegen die Schlafkrankheit und Malaria. Der vielversprechendste neue Wirkstoff gegen erstere heisst Fexinidazol. Das Molekül stammt aus
Marcel Tanner mit dem renommierten Brandenberger-Preis 2023 ausgezeichnet (News)
https://www.swisstph.ch/fr/news/news-detail-1/news/marcel-tanner-mit-dem-renommierten-brandenberger-preis-2023-ausgezeichnet
Marcel Tanner und seine Teams spielten eine Schlüsselrolle bei der Entwicklung von Impfstoffen gegen Malaria und den sogenannten Public Private Partnerships (PPPs), welche die Entwicklung neuer Therapien gegen